New cancer pill enters first human safety tests

NCT ID NCT03264664

Ongoing Disease control Sponsor: Eisai Inc. Source: ClinicalTrials.gov ↗

Summary

This is the first study in people testing a new oral drug called E7386 for advanced cancers that have stopped responding to standard treatments. Researchers will give the drug to about 60 patients with specific tumor types, including liver cancer, to find the safest and most effective dose. The main goal is to check for side effects and determine how much of the drug the body can tolerate.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

California Liver Research Institute

Pasadena, California, 91105, United States
Imperial College Healthcare NHS Trust

London, W2 1NY, United Kingdom
Mayo Clinic Comprehensive Cancer

Jacksonville, Florida, 32224, United States
Mayo Clinic Comprehensive Caner

Phoenix, Arizona, 85054, United States
Mayo Clinic Comprehensive Caner

Rochester, Minnesota, 55905, United States
Royal Free London NHS Foundation Trust, Royal Free Hospital

London, NW3 2QG, United Kingdom
Royal Marsden Hospital NHS Foundation Trust

Sutton, Surrey, SM2 5PT, United Kingdom
The Beatson West of Scotland Cancer Centre

Glasgow, Lanarkshire, G12 0YN, United Kingdom
The Christie NHS Foundation Trust

Manchester, Lancashire, M20 4BX, United Kingdom
USC Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States

Conditions

Explore the condition pages connected to this study.

ADVANCED NEOPLASMS